Position in RLAY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,956,498
+$1,951,026 QoQ
Shares Held
158,017
-45.6% QoQ
Ownership
0.072%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#92
of 256 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RLAY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Verition Fund Management LLC holds $152,220,097 across 64 Biotechnology names. RLAY ranks #13 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
438,746 | $30,997,404 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
159,256 | $21,138,048 | |
| 3 | ABVX |
Abivax S.A.
|
105,791 | $14,097,708 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
184,054 | $6,859,692 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
304,939 | $6,665,966 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
777,738 | $4,853,085 | |
| 7 | CYTK |
Cytokinetics Inc
|
54,889 | $4,675,993 | |
| 8 | RPRX |
Royalty Pharma plc
|
75,000 | $4,205,250 |
All Filings in RLAY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,956,498 | 158,017 | Shares | Sole | 2026-08-14 | |
| 2025-06-30 | $1,005,472 | 290,599 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $364,819 | 139,244 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $372,752 | 90,474 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $539,064 | 76,139 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $90,099 | 13,819 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $160,970 | 19,394 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $178,031 | 16,170 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $494,718 | 58,825 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $432,541 | 34,438 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||